<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05005494</url>
  </required_header>
  <id_info>
    <org_study_id>MG-Entropy</org_study_id>
    <nct_id>NCT05005494</nct_id>
  </id_info>
  <brief_title>Hypnotic and Anti-nociceptive Components of Magnesium</brief_title>
  <official_title>Study of the Hypnotic and Anti-nociceptive Components of Magnesium Using Electroencephalogram Spectral Entropy and Pupillometry During Total Intravenous General Anaesthesia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Liege</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Liege</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of our study is to evaluate the effect of magnesium on the hypnotic effect of&#xD;
      propofol.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of our study is to evaluate the effect of magnesium on the hypnotic effect of&#xD;
      propofol. To achieve this, the investigators will analyse the effect of magnesium on the&#xD;
      brain concentrations of propofol required to achieve a State Entropy value between 50-60,&#xD;
      which corresponds to the recommended depth of anaesthesia. Our study will also evaluate the&#xD;
      intraoperative anti- nociceptive effect of magnesium using pupillometry and its two indices,&#xD;
      PPI and PRD&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2021</start_date>
  <completion_date type="Anticipated">December 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Double blinded prospective randomized controlled trial</intervention_model_description>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Patient, anesthesiologist and surgeon are blinded</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Propofol target concentration</measure>
    <time_frame>through study completion, an average of 3 months</time_frame>
    <description>The target concentration of Propofol TCI (target-control infusion) to achieve a state entropy value between 50-60</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Morphine consumption</measure>
    <time_frame>through study completion, an average of 3 months</time_frame>
    <description>Morphine consumption titrated in the recovery room and morphine equivalents claimed during the first 24 hours postoperatively</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PPI Measure</measure>
    <time_frame>through study completion, an average of 3 months</time_frame>
    <description>PPI (pupillary pain index) by pupillometry with &quot;AlgiScan®&quot; monitoring, before endotracheal intubation and with a State Entropy of 50-60, then every 5 min between endotracheal intubation and surgical incision</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PRD Measure</measure>
    <time_frame>through study completion, an average of 3 months</time_frame>
    <description>PRD (pupillary reflex dilatation) during laryngoscopy maintained for 30 sec, surgical incision and 10min after surgical incision</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Anesthesia</condition>
  <arm_group>
    <arm_group_label>Magnesium sulfate IV</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>10 patients scheduled for thyroidectomy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>10 patients scheduled for thyroidectomy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Magnesium sulfate IV</intervention_name>
    <description>Infusion of magnesium sulphate 50 mg/kg (eq. 0.5ml/kg of magnesium sulphate 100mg/ml)</description>
    <arm_group_label>Magnesium sulfate IV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Infusion of NaCl (sodium chloride) 0.9% (placebo eq. 0.5ml/kg of NaCl 0.9%)</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult &gt; 18 years&#xD;
&#xD;
          -  Patients of both sexes&#xD;
&#xD;
          -  Any patient scheduled for thyroidectomy at the University Hospital of Liege&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Heart failure with left ventricular ejection fraction &lt; 35&#xD;
&#xD;
          -  Renal insufficiency (clearance &lt; 40 mL/min)&#xD;
&#xD;
          -  Neuromuscular diseases&#xD;
&#xD;
          -  Atrioventricular block&#xD;
&#xD;
          -  Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Pierre-Yves Hardy, MD</last_name>
    <phone>003242844858</phone>
    <email>pyhardy@chuliege.be</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Liege,</name>
      <address>
        <city>Liège</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 27, 2021</study_first_submitted>
  <study_first_submitted_qc>August 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 13, 2021</study_first_posted>
  <last_update_submitted>August 13, 2021</last_update_submitted>
  <last_update_submitted_qc>August 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Liege</investigator_affiliation>
    <investigator_full_name>Jean François Brichant</investigator_full_name>
    <investigator_title>Head of Anesthesiology Departement</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Magnesium Sulfate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

